BioPharmSignal logoBioPharmSignal

Biotech News

Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim as Chief Medical Officer

Medicenna Therapeutics Corp. (MDNA)Medicenna Therapeutics Corp.Company update

TORONTO and HOUSTON, April 09, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune diseases, today announced the appointment of

Related news

MDNAMedicenna Therapeutics Corp.2026-08-14 11:00 EST

Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences

MDNAMedicenna Therapeutics Corp.2026-06-26 12:45 EST

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

KYMRKymera2026-07-27 20:01 EST

Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

KYMRKymera2026-07-07 11:00 EST

Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader

FATEFate Therapeutics2026-06-15 12:30 EST

Fate Therapeutics Appoints Laura Hamill to Board of Directors

FATEFate Therapeutics2026-08-14 11:00 EST

Fate Therapeutics Initiates Potentially Registrational RECLAIM-LN Clinical Trial of FT819 for the Treatment of Lupus Nephritis

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

BNTXBioNTech2026-08-03 09:00 EST

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

View all latest news

Medicenna Therapeutics Corp.

IL-2 Superkine Platform Medicenna Therapeutics develops engineered cytokines and fusion proteins intended to improve antitumor immune activity. Its Superkine platform modifies cytokine receptor selectivity, potency and pharmacology. MDNA11 MDNA11 is a long-acting beta-only IL-2 agonist in the Phase 1/2 ABILITY-1 study. It is being...

Recent company news

MDNAMedicenna Therapeutics Corp.2026-08-14 11:00 EST

Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences

MDNAMedicenna Therapeutics Corp.2026-06-26 12:45 EST

Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights

MDNAMedicenna Therapeutics Corp.2026-06-11 11:00 EST

Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms

MDNAMedicenna Therapeutics Corp.2026-06-03 11:00 EST

Medicenna’s MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026

MDNAMedicenna Therapeutics Corp.2026-05-28 13:10 EST

Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs

Stock data

Close
—
Market cap
—
Exchange
NASDAQ
Sector
Biopharma
Location
United States